Status:
UNKNOWN
Population Pharmacokinetics of Tigecycline in Patients Treated With ECMO
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Extracorporeal Membrane Oxygenation
Pharmacokinetics
Eligibility:
All Genders
18+ years
Brief Summary
Tigecycline is a commonly used antibiotic in critically ill patients. The pharmacokinetics (PK) of tigecycline in intensive care unit (ICU) patients can be affected by severe pathophysiological change...
Eligibility Criteria
Inclusion
- critically ill hospitalized males or nonpregnant females aged ≥18 years with severe infections which the treating clinician was treating with tigecycline.
Exclusion
- People who had taken tigecycline in the past week
- People who were pregnant
- People who had coagulation dysfunction
Key Trial Info
Start Date :
January 20 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2022
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04724798
Start Date
January 20 2020
End Date
December 30 2022
Last Update
January 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Southern medical university Nanfang hospital
Guangzhou, China, 510515